Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer. Arlene Siefker-Radtke, MD: Looking at the data presented, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results